Lexaria Bioscience 관리

관리 기준 확인 2/4

Lexaria Bioscience CEO는 Rich Christopher, Aug2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 115.00K 가치에 해당하는 회사 주식의 0.29% 직접 소유합니다. 115.00K. 경영진과 이사회의 평균 재임 기간은 각각 0.3 년과 4 년입니다.

주요 정보

Rich Christopher

최고 경영자

US$519.3k

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.3%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	4yrs

최근 관리 업데이트

Recent updates

CEO

Rich Christopher (54 yo)

less than a year

테뉴어

US$519,317

보상

Mr. Richard C. Christopher, also known as Rich, is Chief Executive Officer of Lexaria Bioscience Corp. from August 31, 2024. He served as Chief Financial Officer and Treasurer of InVivo Therapeutics Holdin...

리더십 팀

이름	위치	테뉴어	보상	소유권
Richard Christopher	Chief Executive Officer	less than a year	US$519.32k	0.29% $ 115.0k
John Docherty	Chairman of the Scientific Advisory Board	9.8yrs	US$414.42k	0% $ 0
Michael Shankman	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Kristin Hamilton	Director of Operations	no data	데이터 없음	데이터 없음
Vanessa Carle	Head of Legal	no data	데이터 없음	0% $ 0
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

0.3yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: LEXX 의 관리팀은 경험 (평균 재직 기간 0.3 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
John Docherty	Chairman of the Scientific Advisory Board	8.8yrs	US$414.42k	0% $ 0
C. Gibson	Chief Medical Advisor & Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Albert Reese	Independent Director	4yrs	US$74.83k	0.063% $ 25.1k
Christopher Bunka	Chairman of the Board	18.3yrs	US$884.84k	1.57% $ 629.1k
Nicholas Baxter	Independent Director	13.5yrs	US$74.83k	0.063% $ 25.3k
William McKechnie	Independent Director	9.3yrs	US$69.83k	0.076% $ 30.3k
Catherine Turkel	Independent Director	2.3yrs	US$74.83k	0.018% $ 7.1k
Philip Ainslie	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Karen Aust	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: LEXX 의 이사회는 경험(평균 재직 기간 4 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/03 05:33
장 마감 주가	2025/01/03 00:00
수익	2024/08/31
연간 수익	2024/08/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Lexaria Bioscience Corp. 4 애널리스트 중 2 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Ammar Shah	Eight Capital
Yi Chen	H.C. Wainwright & Co.
Michael Okunewitch	Maxim Group

Lexaria Bioscience 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Chief Executive Officer recently bought US$51k worth of stock

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Recent updates

Lexaria Bioscience Corp. Begins Dosing in its Phase 1B, 12-Week Chronic Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces the Creation of Its New Scientific Advisory Board

Lexaria Bioscience Corp. Announces Engagement of Contract Research Organization to Design and Execute Human Pilot Study Evaluating Dehydratech-Liraglutide Against Saxenda Injectable Liraglutide

Chief Executive Officer recently bought US$51k worth of stock

Consensus revenue estimates fall by 13%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria Bioscience Corp.'s GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Lexaria Bioscience Corp. Receives Final 12-Week Body Weight and Blood Sugar Results from All 12 Study Groups of the Recently Completed Diabetes Animal Study

Lexaria Bioscience Corp., Annual General Meeting, Jan 14, 2025

Lexaria Bioscience Corp. Announces Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives Partial 12-Week Body Weight Results from the Recently Completed Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $5 million.

Lexaria Bioscience Begins Dosing in Human Pilot Study for Oral Tirzepatide Using Dehydratech Technology

Lexaria Bioscience Corp. Appoints Michael Shankman as Chief Financial Officer

Lexaria Bioscience Corp Receives Independent Review Board Approval to Begin Human Pilot Study #3

Lexaria Bioscience Corp. Announces Chief Executive Officer Changes

Lexaria Bioscience Corp. Announces Second GLP-1 Human Pilot Study Shows Zero Adverse Events in Dehydratech-Processed Rybelsus Oral Capsules

First Results from Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Bioscience Corp. Receives 4-Week and 8-Week Blood Sugar Results from Ongoing Animal Study WEIGHT-A24-1

Lexaria Bioscience Corp. Announces Positive Results from Lexaria's Molecular Characterization Study

Consensus revenue estimates fall by 24%

Lexaria Bioscience Corp. Announces Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2

Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study

Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study

Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study

Consensus revenue estimates increase by 24%

Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study

Second quarter 2024 earnings released: US$0.06 loss per share (vs US$0.22 loss in 2Q 2023)

Lexaria Appoints Nelson Cabatuan as Chief Financial Officer

Lexaria Bioscience Corp., Annual General Meeting, Apr 23, 2024

Lexaria to Begin Diabetes and Weight Loss Animal Study Well-A24-1

Lexaria Bioscience Corp. Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. has filed a Follow-on Equity Offering in the amount of $3.599992 million.

Lexaria Bioscience Corp. Submits Investigational New Drug Application

Consensus revenue estimates increase by 100%

Lexaria Bioscience Corp. Unveils Extensive Planned 2024 GLP-1 Study Program

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.29 loss in 1Q 2023)

Lexaria Bioscience Corp. Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream

Lexaria Bioscience Corp. Improves Delivery, Efficacy of Glp-1 Agonists Through Proprietary Drug-Delivery Platform

Lexaria Bioscience Corp. Announces Positive Final Results from its Recently Completed Human Pilot Study #1 for the Oral Performance of the Rybelsus(R)-Branded GLP-1 Drug Semaglutide

Lexaria Bioscience Corp. Announces Investigational New Drug Application Filing Update

Consensus revenue estimates decrease by 20%, EPS upgraded

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Lexaria's Technology Improves the Oral Performance of the Rybelsus(R-Branded GLP-1 Drug Semaglutide in Human Pilot Study

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lexaria Bioscience Corp. has completed a Follow-on Equity Offering in the amount of $0.114546 million.

Lexaria Bioscience Corp. Evaluates Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement Set Forth in Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Lexaria Bioscience Corp. Announces Its Intention to Launch New Human and Animal Studies to Examine Dehydratech™-Processed Glucagon-Like Peptide-1

Lexaria Bioscience Corp. Provides Update on Investigational New Drug Application Progress

Consensus revenue estimates increase by 38%, EPS downgraded

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp.'s DehydraTECH-Nicotine Faster than ZYN and on

Lexaria Bioscience Corp Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD

Lexaria Bioscience Corp Grants Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products

New major risk - Revenue and earnings growth

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Lexaria Bioscience Receives Nasdaq Bid Price Deficiency Notice

Lexaria's DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study